THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
申请人:Lemieux Rene M.
公开号:US20150031627A1
公开(公告)日:2015-01-29
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
[EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS MÉTHODES D'UTILISATION
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2015010297A1
公开(公告)日:2015-01-29
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
[EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS PROCÉDÉS D'UTILISATION
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2013107291A1
公开(公告)日:2013-07-25
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
[EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET UTILISATION DE CEUX-CI
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2015010626A1
公开(公告)日:2015-01-29
Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.
提供的是治疗上有效的化合物及其在制造用于治疗具有IDH1突变等位基因的癌症的药物中的应用。
[EN] DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'OXAZOLE À SUBSTITUANT DIAZASPIROALCANONE EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE SPLÉNIQUE
申请人:AB SCIENCE
公开号:WO2015144614A1
公开(公告)日:2015-10-01
The present invention is concerned with diazaspiroalkanone- substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, and degenerative disorders. In particular, the presently disclosed compounds are Syk inhibitors.